Litcius/Paper detail

Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma

Vicky Kritikos, Erin S. Harvey, Sean Stevens, Constance H. Katelaris, David Langton, Janet Rimmer, Claude S. Farah, Andrew Gillman, Mark Hew, Naghmeh Radhakrishna, Dennis Thomas, Peter G. Gibson, Melissa Baraket, Philip Bardin, Jeffrey J. Bowden, Simon Bowler, Jimmy Chien, Li Ping Chung, Christopher Grainge, Nicholas Harkness, Zinta Harrington, Christine Jenkins, Gregory P. Katsoulotos, Vanessa M. McDonald, Joy Lee, Matthew Peters, Helen K. Reddel, Paul N. Reynolds, Pathmanathan Sivakumaran, John W. Upham, Peter A.B. Wark

2022The Journal of Allergy and Clinical Immunology In Practice14 citationsDOI

Topics & Concepts

MepolizumabMedicineEosinophilicAsthmaPhenotypeEosinophilic esophagitisDermatologyImmunologyInternal medicineEosinophilPathologyGeneticsDiseaseGeneBiologyAsthma and respiratory diseasesEosinophilic EsophagitisDelphi Technique in Research
Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma | Litcius